Recombinant Zika Virus NS1 Protein, His-tagged
Specification
Related Products
| Cat#: |
ZIK-636 |
| Product Name: |
Recombinant Zika Virus NS1 Protein, His-tagged |
| Description: |
Zika virus NS1 protein 1 (Non-Structural protein 1) has been manufactured in response to the unmet need for highly purified, concentrated protein for use in serological based diagnostic assays. Zika virus NS1 protein is engineered in human cells using state-of-the-art expression and purification techniques. Zika virus NS1 has been produced to the same standards as other NS1 proteins, and is presented as a highly purified liquid protein. |
| Gene: |
NS1 |
| Species: |
Zika Virus (Uganda Strain) |
| Source: |
human cells |
| Synonyms: |
Zika Virus NS1 (Uganda Strain) |
| Formulation: |
DPBS pH 7.4 |
| Concentration: |
0.6 mg/mL (Specification: 0.4-1.0 mg/mL by BCA assay) |
| Purity: |
>90% by SDS-PAGE |
| Notes: |
This product is intended for research and manufacturing uses only. It is not a diagnostic device. The user assumes all responsibility for care, custody and control of the material, including its disposal, in accordance with all regulations. |
| Tags: |
C-terminal His |
| Sequence Strain: |
Uganda MR 766 |
| Background: |
Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since been spread to South Asia and recently to South America. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections.The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly.
Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus.
Analysis of Zika virus sequences from infected patients have shown that the strain circulating in South America in 2015 differs to the strain originally isoloated in 1947 in Uganda (the "Uganda" strain). The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain. 7. |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
